Aptevo Therapeutics Inc. (NASDAQ: APVO)

Aptevo Therapeutics Inc. (APVO) is a clinical-stage biotechnology company operating in the healthcare industry, specifically focused on developing novel immunotherapy candidates for the treatment of various forms of cancer.

The company's main business activities revolve around the development of immunotherapy candidates using its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. These platforms are designed to generate monospecific, bispecific, and multi-specific immunotherapeutic proteins, providing a unique signaling response and engaging disease targets in a novel manner. Aptevo's operations span across multiple countries, with a significant presence in the United States.

Aptevo's revenue is generated through the development and commercialization of its product candidates. These include APVO436, ALG.APV-527, APVO603, APVO442, and APVO711. Each of these candidates targets specific cancer antigens and immune cells to stimulate an anti-tumor immune response.

APVO436 is a bispecific ADAPTIR candidate that targets CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing CD123. The company has completed a Phase 1b dose expansion clinical trial and plans to initiate a Phase 1b/2 trial in the first half of 2024. APVO436 has received orphan drug designation from the FDA for the treatment of acute myelogenous leukemia.

ALG.APV-527 is a bispecific ADAPTIR candidate that targets 4-1BB and 5T4, a tumor antigen overexpressed in various types of cancer. The company is currently conducting a first-in-human Phase 1 clinical trial, which started in the first quarter of 2023. ALG.APV-527 is designed to reactivate antigen-primed T-cells and has the potential to treat a broad range of solid tumors.

APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate that targets 4-1BB and OX40, both members of the TNF-receptor family. The company is conducting IND-enabling studies for APVO603.

APVO442 is a preclinical bispecific ADAPTIR candidate that targets PSMA and CD3. The company is conducting preclinical studies for APVO442.

APVO711 is a preclinical dual mechanism bispecific ADAPTIR candidate that targets PD-L1 and CD40. The company is conducting preclinical studies for APVO711.

Aptevo's position within the industry is competitive, with several established players in the market. However, the company's proprietary technologies, such as ADAPTIR and ADAPTIR-FLEX, provide a competitive advantage. Aptevo's competitors include companies such as Affirmed, Arcellx, AvenCell, Cellectis, Macrogenics, Inc. / Gilead, ImmunoGen, Menarini Group, and Sanofi, among others.

Aptevo has established collaborations with other companies, including Alligator Bioscience AB, to develop its product candidates. The company's collaboration with Alligator Bioscience AB is focused on the development of ALG.APV-527, a bispecific antibody candidate targeting 4-1BB and 5T4.